SCHEMBL6035293

SCHEMBL6035293

CCOC(=O)c1cn(-c2ccc(C(F)(F)F)cc2)nc1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 7/20 0.46
RAB9A P51151 7/20 0.46
LMNA P02545 1/20 0.46
MLYCD O95822 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
GLA P06280 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
CA12 O43570 5/20 0.43
CA9 Q16790 5/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
ADORA1 P30542 1/20 0.42
DGAT1 O75907 1/20 0.42
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19807432 0.91 NPSR1 (0.47) NPSR1MAPK1NPC1RAB9ALMNA
SCHEMBL6034721 0.84 SMN1; SMN2 (0.57) NPC1RAB9ALMNAMLYCDSMN1; SMN2
SCHEMBL4853920 0.84 NPC1 (0.51) NPSR1MAPK1NPC1RAB9ALMNA
SCHEMBL4296566 0.84 NPSR1 (0.61) NPSR1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16635806 0.82 NPSR1 (0.48) NPSR1MAPK1NPC1RAB9ALMNA
SCHEMBL6035573 0.80 DDX3X (0.41) NPC1RAB9ALMNAMLYCDSMN1; SMN2
SCHEMBL14052991 0.80 MAPT (0.51) NPSR1MAPK1NPC1RAB9ALMNA
SCHEMBL16635022 0.78 NPC1 (0.58) NPSR1NPC1RAB9ALMNAMLYCD
SCHEMBL16635591 0.78 NPC1 (0.55) NPSR1NPC1RAB9ALMNAMLYCD
SCHEMBL29332811 0.77 NPC1 (0.60) NPSR1MAPK1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 NPSR1 2478/4885MAPK1 717/4885NPC1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.